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A B S T R A C T
Purpose
Recommendations for women at high risk of ovarian cancer include periodic gynecologic
screening (GS) and prophylactic bilateral salpingo-oophorectomy (PBSO). The aim of the
current study was to determine the quality-of-life (QOL) effects of PBSO versus GS.
Patients and Methods
Questionnaire data were obtained from 846 high-risk women who had participated in this
nationwide, cross-sectional, observational study. Forty-four percent of the women had under-
gone PBSO, and 56% had opted for GS. Topics addressed by the questionnaire included generic
QOL, cancer-specific distress, endocrine symptoms, and sexual functioning.
Results
No statistically significant between-group differences were observed in generic QOL (Short
Form-36), with women in both the PBSO and GS groups scoring similarly to the general
population. Compared with GS, PBSO was associated with fewer breast and ovarian cancer
worries (P  .001) and more favorable cancer risk perception (P  .05). However, the PBSO
group reported significantly more endocrine symptoms (P  .001) and worse sexual
functioning (P  .05) than the GS group. Eighty-six percent of women would choose PBSO
again, and 63% would recommend it to a friend with familial risk of ovarian cancer.
Conclusion
PBSO had no measurable adverse impact on generic QOL of high-risk women. The favorable
effects of PBSO in terms of reduced cancer worries and low perceived cancer risk need to
be weighed against the increase in endocrine and sexual symptoms. Balanced information
will help clinicians and high-risk women to make informed decisions about the optimal
preventive health strategy.
J Clin Oncol 23:6890-6898. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Ovarian cancer is one of the most common
and lethal of gynecologic malignancies. In
the Netherlands, the average age-adjusted
incidence and mortality rates are 13.1 and
9.6 per 100,000 women, respectively, which
are comparable to the rates observed in the
United States.1,2 A family history of ovarian
cancer is considered to be one of the stron-
gest predictors of developing the disease,
and it is estimated that 5% to 10% of all
ovarian cancer patients have a hereditary
basis.3,4 Female carriers of a BRCA1 gene
mutation have a lifetime ovarian cancer risk
in the range of 39% to 54%.5,6 Women with
a BRCA2 mutation have a lower ovarian
cancer risk (11% to 23%), but this is still
approximately 10-fold greater than the risk
of women in the general population.5,6
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Principal preventive health strategies for women at
increased risk of ovarian cancer include periodic gyneco-
logic screening (GS) and prophylactic bilateral salpingo-
oophorectomy (PBSO), which are aimed at early cancer
detection and cancer risk reduction, respectively. Although
annual GS is offered as a basic surveillance strategy to high-
risk women, its efficacy has yet to be established.7 Current
techniques, such as transvaginal sonography and CA-125
serology yield a significant number of false-positive or false-
negative results, leading either to unnecessary medical in-
vestigations or to undetected early-stage malignancies.
Because early ovarian cancer is asymptomatic and the avail-
able techniques have not been demonstrated to be effective
for early diagnosis in the general population,8 the majority
of diagnosed ovarian cancers are characterized by advanced
stages and, therefore, by a poor prognosis.9
In view of the uncertainty surrounding screening pro-
cedures, high-risk women may opt for surgical removal of
their ovaries and fallopian tubes. PBSO reduces ovarian
cancer risk inBRCA1/2mutation carriers by 96%andbreast
cancer risk by 53%.10,11 However, PBSO does not eliminate
the risk of ovarian cancer entirely because 1% to 2% of
women may develop peritoneal carcinoma.10-12 Adverse
effects associated with prophylactic surgery in premeno-
pausal women are loss of fertility and immediate onset of
menopause as a result of estrogen deprivation, including
vasomotor symptoms and possible sexual dysfunction.13,14
Estrogen deprivation may also lead to higher risk of devel-
oping osteoporosis.15 To relieve climacteric symptoms,
hormone replacement therapy (HRT) is often prescribed.16
However, the effectiveness of HRT in combating symptoms
associated with surgically induced menopause has not yet
been established.
Thus far, only four studies have explicitly focused on
quality-of-life (QOL) effects associatedwith PBSOor PBSO
versus GS.17-20 Several studies17-19 have reported beneficial
effects of PBSO on cancer-specific distress (eg, cancer wor-
ries and anxiety) and perceived cancer risk but adverse effects
on sexual functioning and vasomotor symptoms. In these
studies, genericQOLwas not affected by prophylactic surgery,
withoophorectomizedwomenreporting similar levelsofQOL
as women in the general population.17,18 The only study that
has compared theQOL effects of PBSO andGS yielded some-
what conflicting results.20Oophorectomizedwomen reported
significantlyworse genericQOL thanwomen in theGS group;
however, no comparisons with the general population were
provided.Additionally, PBSOwasnot found to relieve cancer-
specificdistress or toworsen sexual functioning.Although this
latter studywas the first to provide a comparison of psychoso-
cial effects ofPBSOandGS, its resultsmaynotbe generalizable
to the entire population of high-risk women. It was a single-
center study with a small sample size (PBSO, n  29; GS,
n 28), and not all statistical analyses controlled for possible
confoundingmedical variables (eg, DNA status and history of
breast cancer). In this report,wepresent the results of anation-
wide, multicenter, cross-sectional, observational study that
was conducted todeterminepossible differences in the generic
and condition-specific QOL effects of PBSO versus GS.
PATIENTS AND METHODS
Sample and Procedures
Study participants were recruited from the gynecology de-
partments of eight hospitals in the Netherlands. Women were
eligible for enrollment if they were between 30 and 75 years of age,
came from a hereditary breast or ovarian cancer family, and had
sought advice from a gynecologist on preventive measures at one
of the eight participating gynecology clinics between 1996 and
2001. Patients were excluded fromparticipation if they had under-
gone oophorectomy because of any suspicious changes in the
ovaries as detected bymedical examination, including both benign
and malignant conditions; if oophorectomy was performed as
adjuvant treatment for breast cancer; or if they had terminal
cancer or any other severe medical comorbidity.
Eligible women received an invitation letter by mail, an in-
formed consent form, a questionnaire, and a postage-paid return
envelope. In case of nonresponse within 2 weeks, systematic re-
minders by mail and telephone were used. Patients were classified
as nonrespondents if they actively declined to participate by mail
or telephone or if they could not be reached after multiple at-
tempts. Age and the type of ovarian cancer prevention strategy
used (PBSO v GS) were the only available data that could be
registered for nonrespondents. The study was approved by the
institutional review boards of all participating hospitals.
Measure: Generic QOL
To assess genericQOL, four of the eight subscales of the Short
Form-36 (SF-36) Health Survey21,22 (general health perceptions,
vitality, role limitations caused by emotional problems, and gen-
eral mental health) and the global QOL item of the European
Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire C3023 were used. All raw scale scores were
linearly converted to a 0 to 100 scale, with higher scores indicating
higher levels of QOL.24,25 Cronbach’s  coefficients in the present
sample for the four SF-36 scales ranged from .80 to .86.
Measure: Condition-Specific QOL
Condition-specific QOL included measures of cancer-specific
distress (intrusive thoughts, cancer worries, and anxiety), cancer risk
perception, endocrine symptoms, and sexual functioning.
Cancer-specific distress: Intrusive thoughts, cancer worries, and
postoperative anxiety. The seven-item intrusion subscale of the
Impact of Events Scale (IES)26,27 measures the frequency of intru-
sive thoughts experienced because of a specific stressor, which was
defined in the present study as an increased risk of developing
breast or ovarian cancer. A higher sum score (range, 0 to 35)
corresponds to more distress (Cronbach’s   .90). The recom-
mended cutoff sum score for identifying persons likely to meet
criteria for post-traumatic stress syndrome (PTSD) is 20.28
Five Likert-type items, adapted from Lerman,29 were used to
assess worries about breast and ovarian cancer. These included the
frequency of ovarian and breast cancer worries (two items), the
impact of cancer worries on mood and daily functioning (two
items), and the frequency of worries about the possible cancer risk
Quality of Life and Prophylactic Oophorectomy
www.jco.org 6891
131.174.209.229
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on July 11, 2012 from
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
in familymembers (1 rarely or never, 2 sometimes, 3 often,
4 all the time). These five items were summed to create a cancer
worry scale (possible range, 5 to 20), with higher scores represent-
ing more frequent worries in the last 4 weeks (Cronbach’s
 .70). Additionally, women in the PBSO group were asked to
rate the extent to which PBSO reduced their anxiety about devel-
oping ovarian and breast cancer, with response choices varying on
a 4-point scale from not at all to very much.
Self-perceived cancer risk. Two items adapted from previous
studies30,31 assessed patients’ current perceptions of their breast
cancer risk. Women were asked to rate their self-perceived risk on
a scale 0% to 100%, where 0 corresponded to no risk at all and 100
corresponded to being certain about developing cancer in the
future.Women in the PBSO groupwere also requested to estimate
(retrospectively) their presurgery risk of developing breast cancer.
Endocrine symptoms and sexual functioning. The Functional
Assessment of Cancer Therapy–Endocrine Symptom, an 18-item
endocrine symptom scale, was used to assess menopausal symp-
toms.32 Occurrence of each symptom in the last 4 weeks was
scored on a 5-point Likert-type scale, ranging from not at all to
very much. Item scores were summed to obtain a scale score
(range, 0 to 72), with lower values indicating more menopausal
symptoms. The Cronbach’s  in the present study was .81.
The Sexual Activity Questionnaire (SAQ)33 was used tomea-
sure sexual functioning. The SAQ consists of the following three
scales: pleasure (six items on desire, enjoyment, satisfaction, and
current frequency of activities), discomfort (two items on vaginal
dryness and pain and discomfort during penetration), and habit
(frequency of sexual activity compared with the usual level).
Lower scores represent poorer sexual functioning. In the present
sample, Cronbach’s  coefficients for pleasure and discomfort
scales were .82 and .77, respectively. The SAQ was introduced
during the course of the study and, thus, was administered to only
a subset of women (n 513) from five study centers.
Measure: Satisfaction With Preventive
Health Strategies
A series of single items was used to assess the level of satisfac-
tionwith or regrets about the decision to undergo PBSOorGS.On
a 5-point scale, varying from completely disagree to completely
agree, women were asked to indicate their level of agreement or
disagreement with the following statements: (1) I am satisfiedwith
the decision I have made, and (2) I have regrets about the decision
I havemade.Womenwho chose agree or completely agree as their
response to the first or second statement were considered as being
satisfied with their decision on the preventive health option or as
having regrets about it, respectively. Additionally, women were
asked two questions about whether or not they would choose to
undergo the same preventive health strategy again and about
which preventive option they would recommend to a friend in a
similar situation.
Medical and Sociodemographic Data
Medical data were obtained from two sources (a question-
naire and hospital medical records). In case of discrepancies be-
tween self-reported and medical record data, the latter were
considered as the primary information source.
The questionnaire contained a series of questions on repro-
ductive history, personal history of cancer and recent treatment
for cancer, prevalence of ovarian and breast cancer among rela-
tives, prophylactic ovarian and breast surgery, and use of HRT.
Menopausal status was determined through a series of questions
on menstrual history and symptoms during the 6 months preced-
ing PBSO or at the present moment for women who had opted for
GS. Premenopause was defined as regularmenstrual periods, peri-
menopause was defined as irregular periods, and postmenopause
was defined as complete cessation of menstrual periods for at least
1 year. Women who had had PBSO were classified as postmeno-
pausal. Additionally, clinical variables, such as DNA status, type of
prophylactic ovarian or breast surgery, possible use of HRT, his-
tory of (breast) cancer, its stage at diagnosis, and cancer treatment,
were retrieved from the medical records. Sociodemographic vari-
ables (age, marital status, education, and employment) were ob-
tained from the questionnaire.
Statistical Analysis
Descriptive statistics (frequencies, means, and standard devi-
ations [SD]) were generated to characterize the sample in terms of
sociodemographics and medical variables. Student’s t tests and 2
tests were used to explore potential differences in the background
characteristics of women who had undergone PBSO and women
who had opted for GS.
To test for the statistical significance of group differences in
generic and condition-specific QOL, we used one-way analysis of
covariance (ANCOVA) controlling for possible confounders (age,
BRCA1/2 status, parity, history of breast cancer, and prophylactic
mastectomy [PM]). To examine the magnitude of differences be-
tween the PBSO and GS groups, effect sizes based on differences
between mean scores divided by the pooled SD were calculated. In
accordance with Cohen,34 effect sizes of 0.20, 0.50, and 0.80 were
considered small, medium, and large, respectively. Using ANCOVA,
we also investigated possible differences in the SF-36 mean scale
scores between the participating high-risk women and women of
similar age from the general Dutch population. The SF-36 general
population normative datawere based on the sample reported earlier
by Aaronson et al.22
A multivariate logistic regression analysis was conducted to
investigate the effects of the type of ovarian cancer prevention
(GS v PBSO) on the odds of the presence of cancer worries, when
controlling for the potential confounders. Separate items of the
cancer worry scale were dichotomized (eg, worried v not worried),
with the original categories (sometimes, often, and all the time)
describing the frequency of worries and their impact onmood and
functioning collapsed into one category (worried). The purpose of
this analysis was to determine which specific aspects of distress
contributed the most to a PBSO-GS difference.
Within the PBSO group, we also examined whether meno-
pausal status (premenopausal v postmenopausal) at the time of
ovarian surgery had a significant impact on the current levels of
QOL. Additionally, in an ANCOVA model, we controlled for the
time since surgery and current HRT use.
All statistical analyses were carried out using SPSS version
11.5.0 (SPSS Inc, Chicago, IL). Because of multiple testing, the
significance level was set at P  .01. P values between .01 and .05
were considered to be marginally significant. All statistical tests
were two sided.
RESULTS
Study Sample
On the basis of the hospital census data (Fig 1), we
identified 1,205 high-risk patients who were potentially
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eligible for participation in the study. After an additional
medical record audit, 121 women were excluded because of
oophorectomy carried out as treatment for benign or ma-
lignant conditions (n  94), death (n  23), terminal
cancer (n  3), or severe psychiatric problems (n  1). In
total, 858 (79%) of 1,084 eligible women returned the ques-
tionnaires. The main reasons for nonparticipation were
lack of motivation (n  137), poor health (n  8), and
emotional problems (n 8). The data of 12 women had to
be excluded; five of these women reported that the ques-
tionnaire was not applicable to their present situation be-
cause their cancer risk was found not to be increased
according to DNA testing, five women had a high percent-
age ( 50%) of missing values, and two women reported
having undergone an oophorectomy before 1996. There
were no statistically significant differences between the re-
spondents and nonrespondents regarding the type of ovar-
ian cancer prevention and mean age (data not shown).
The final study sample (n  846) consisted of 369
women (44%) who had undergone PBSO and 477 women
(56%) who had opted for periodic GS (pelvic examination,
transvaginal sonography, and CA-125 serology). Among
BRCA1/2 mutation carriers (n  368), 265 women (72%)
opted for PBSO, and 103 women (28%) opted for GS.
The demographic and clinical characteristics of the
sample are listed in Table 1. Compared with the women in
the GS group, the women in the PBSO group were signifi-
cantly older and were significantly more likely to have been
diagnosed with breast cancer, to be BRCA1/2 mutation
carriers, and to have undergone (unilateral or bilateral) PM
(all P  .001). Women with less education and women
having at least one child were also more likely to undergo
PBSO, although these associations only reached marginal
levels of statistical significance (all P  .05). After PBSO,
slightly more than one third of women had used HRT.
Generic and Condition-Specific QOL
Table 2 lists mean scores and SDs of the QOLmeasures
for the PBSOandGS groups.Overall, the study respondents
exhibited high levels of generic QOL as assessed by the
SF-36, and no significant differences were found between
the PBSO and GS groups. The SF-36 scores of both the
PBSO and GS groups were, on average, not significantly
different from those of similarly aged women from the
general population.
There were no significant group differences in mean
levels of intrusive thoughts about cancer, and similar per-
centages of the PBSO and GS groups (9% to 10%) reported
intrusive thoughts (sum score 20) severe enough to indi-
cate the possible presence of PTSD (Table 2). However,
women who had undergone PBSO reported significantly
fewer cancer worries (scale mean, 7.0; range, 5 to 14) than
Fig 1. Flow chart for recruitment of
women at increased risk for ovarian cancer
in a study to evaluate quality-of-life (QOL)
effects of prophylactic oophorectomy ver-
sus periodic gynecologic screening.
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women in the GS group (scale mean, 7.9; range, 5 to 20;
P  .001; effect size  0.44). The effect of PM and the
interaction effect of prophylactic oophorectomy (yes v no)
and PM (yes v no) were (marginally) significant (P  .05
and .01, respectively). Women who had undergone both
PBSO and PM (PBSOPM) reported significantly lower
levels of cancer worries (mean, 6.6; range, 5 to 13) com-
pared with mastectomized women undergoing GS (mean,
8.1; range, 5 to 20). Regarding specific aspects of cancer
worries (Table 3), significantly fewer women in the PBSO
group indicated being worried about their ovarian cancer
risk (P  .001), being worried about cancer risk among
their familymembers (P .05), and that cancerworries had
affected their mood (P .001) and functioning (P .01).
Eighty-two percent and 45% of oophorectomized women
reported that their anxiety about developing ovarian and
breast cancer, respectively, had decreased substantially
since their surgery (Table 2); for the PBSOPM group,
Table 1. Demographic and Medical Characteristics of the Sample by Preventive Health Strategies for Ovarian Cancer: PBSO Versus GS
Characteristic
% of Patients
PPBSO (n  369) GS (n  477)
Age, years  .001
Mean 49 47  .001
SD 8 9
30-35 1.6 11.2
36-45 33.9 37.9
46-55 45.5 33.3
 55 19.0 17.6
Marital status .520
Married/cohabitating 83.6 81.8
Unmarried/without partner 16.4 18.2
Educational level .019
Primary school/lower level high school 22.2 18.3
Middle level high school 49.3 44.1
Advanced vocational/university 28.5 37.6
Parity .003
Null parity 11.9 19.5
At least one child 88.1 80.5
Current menopausal state
Premenopausal 62.1
Peri/postmenopausal 100 37.9
Menopausal state before PBSO
Premenopausal 38.2 —
Peri/postmenopausal 61.8 —
Previous or present use of HRT 36.9† 5.9  .001
DNA status  .001
BRCA1/2 carrier 71.8 21.6
Nonconclusive 13.3 24.9
Not tested/other 14.9 53.5
History of breast cancer, yes 49.3 34.0  .001
Current use of tamoxifen, yes 5.1 3.4 .194
Prophylactic mastectomy, yes 45.5 13.2  .001
Self-reported time since first visit to gynecologist because of high-risk status, years .202
Mean 4.1 4.3
SD 2.4 3.2
Median 4.0 4.0
Type of prophylactic oophorectomy
Laparoscopy 80.1 —
Laparotomy 19.9 —
Time since PBSO, years
Mean 2.8 —
SD 1.9 —
Median 2.0 —
Abbreviations: PBSO, prophylactic bilateral salpingo-oophorectomy; GS, gynecologic screening; SD, standard deviation; HRT, hormone replacement therapy.
Including women with surgically induced menopause as a result of PBSO.
†Use of HRT following PBSO.
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these percentages were 90% and 57%, respectively. Compa-
rable data were not available for the GS group.
Adjusting for possible confounders, the perceived risk
of developing breast cancer was marginally significantly
lower among women who had undergone PBSO than
among women in the GS group The effect of PM was
statistically significant (P  .001; effect size  0.58), with
the lowest estimated risk being in the PBSOPM group
(mean  SD, 12.9  11.2) and the highest risk being in
women undergoing GS only (mean SD, 46.9 26.0). For
the entire PBSO group, the perceived risk of breast cancer
had decreased, on average, by 29.1 points on a scale 0 to 100
compared with before ovarian surgery (retrospective esti-
mate). For women who had also undergone PM, the de-
crease was 51.3 points (data not shown).
No significant differences in the level of sexual activ-
ity were observed between the PBSO and GS groups
(Table 2). However, women in the PBSO group re-
ported marginally significantly more discomfort (vaginal
dryness and dyspareunia; P  .05), less pleasure and
satisfaction during sexual activities (P .05), and signif-
icantly more endocrine symptoms (P  .001) than the
GS group. No significant differences were observed be-
tween HRT users and nonusers after ovarian surgery in
the levels of endocrine symptoms and sexual functioning
(data not shown). Menopausal status at the time of PBSO
(premenopausal v postmenopausal) and the time since
PBSO were not significantly related to the current levels
of generic and condition-specific QOL reported by oo-
phorectomized women (data not shown).
Table 2. QOL Assessments by Preventive Health Strategies for Ovarian Cancer: PBSO Versus GS
QOL
PBSO
(n  369)
GS
(n  477)
P (PBSO v GS)
Effect
Size
Population
Norm
(n  487)
Mean SD† Mean SD† Mean SD
Generic QOL,‡ score
Global health status 74.9 19.0 76.1 19.4 .51
General health perceptions 70.3 22.4 70.9 19.7 .73 70.0 20.0
Vitality 62.7 18.7 64.0 17.2 .55 65.1 19.5
Mental health 73.7 15.9 72.9 15.7 .29 74.1 18.2
Role–emotional 75.4 37.2 79.2 33.8 .95 79.8 35.1
Condition-specific QOL
Intrusive thoughts§
Sum score 6.8 7.8 7.0 7.7 .37
Patients scoring  20, % 8.9 9.6 .73
Cancer worries,§ score 7.0 1.9 7.9 2.2  .001 0.44
Women reporting a large decrease in anxiety about
ovarian cancer after PBSO, %
82.1
Women reporting a large decrease in anxiety about
breast cancer after PBSO, %
44.9
Perceived breast cancer risk before PBSO (0-100),
score
58.6 29.5
Currently perceived breast cancer risk (0-100),
score
29.5 28.0 39.0 28.2  .05 0.34
Endocrine symptoms, score 56.0 9.5 59.7 9.6  .001 0.34
Sexually active women, %¶ 75 81 .11
Sexual functioning,† score
Pleasure 9.6 3.5 10.7 3.2  .05 0.33
Discomfort 4.4 1.7 5.1 1.4  .05 0.45
Habit 0.9 0.5 0.9 0.5 .73
Abbreviations: QOL, quality of life; PBSO, prophylactic bilateral salpingo-oophorectomy; GS, gynecologic screening; SD, standard deviation; ANCOVA,
analysis of covariance.
Population norm scores were available only for the Short Form-36 scales (general health perceptions, vitality, mental health, and role–emotional). None of
the comparisons between the general population scores and those of high-risk women (PBSO and GS groups) were statistically significant (all P  .3). All
analyses were adjusted for age.
†Unadjusted means, P values, and effect sizes for the main effect. PBSO versus GS in ANCOVA. All analyses were controlled for age, DNA status, parity,
history of breast cancer, and prophylactic mastectomy. Effect sizes were calculated according to the following formula: Cohen’s d  MPBSO  MGS/pooled,
where (MPBSOMGS), PBSO
2, and GS
2 indicate, respectively, a difference in mean QOL scores and score variances of the PBSO and GS groups and where
pooled  √(PBSO2  GS2)/2. Effect sizes are indicated only for P  .05.
‡Higher scores correspond to better functioning or less symptoms.
§Higher scores indicate more intrusive thoughts or worries.
Lower scores indicate higher levels of endocrine symptoms.
¶The Sexual Activity Questionnaire was administered to a smaller sample of women (PBSO, n  248; GS, n  265). Scores for sexual functioning apply
only to women who reported that they had been sexually active in the last 4 weeks. Higher scores represent higher levels of sexual functioning.
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Satisfaction With Preventive Health Strategies
Ninety-seven percent of women who had undergone
PBSO reported being satisfied with the decision they had
made compared with 82% of women in the GS group (P
.01). Regrets about the decision on the preventive health
strategywere expressed by 5%of the PBSOgroup and 6%of
theGS group (P .05). Eighty-six percent of womenwould
choose PBSO again, and 63% would recommend it to a
friend with familial risk of ovarian cancer. In the GS group,
14%, 4%, and 15% of women intended to undergo PBSO
within 5 years, within 10 years, and at some unspecified
time in the future, respectively. Dissatisfaction with GS was
not related significantly to the intention to undergo PBSO
in the future.
DISCUSSION
To our knowledge, this is the largest cross-sectional, obser-
vational study to date that describes the psychosocial issues
of ovarian cancer prevention in high-risk women. The re-
sults provide a comprehensive assessment of the generic
and condition-specific QOL in 846 women who had opted
either for PBSO or periodic GS.
All study participants reported high levels of generic
QOL that were not significantly different from the QOL
levels of women in the general Dutch population. Despite
the fact that PBSO is an irreversible procedure with major
consequences for the bodily hormonal balance, which, in
turn, may affect the level of the patients’ general well-being,
we found no adverse impact of PBSO on generic QOL.
These results are consistent with earlier findings17,18 but in
contrast with one study20 that suggested impairments in
generic QOL as a result of PBSO. The discrepant results of
the latter studymay be a result of methodologic issues, such
as a small sample size and the lack of statistical control for
possible confounding medical factors.
Our results indicate that PBSO is associated with sig-
nificantly lower levels of cancer worries compared with GS,
with the fewest worries being expressed by women who had
undergone both PBSOandPM.Additionally, 45%and 82%
of women also indicated that PBSO had led to a large
decline in anxiety about breast and ovarian cancer, respec-
tively. As expected, the anxiety reduction was even larger
for women who had undergone both prophylactic ovarian
and breast surgery. Our findings are in line with other
reports17-19,35 that have found a postsurgery reduction in
cancer-specific distress but contrast with the results of Fry et
al,20 who found no beneficial effects of PBSO over GS on
cancer worries. This discrepancy may be a result of the fact
that Fry et al20 used a different measure of cancer worries36
than the measure used in our and other studies. Also, their
sample was small, and it may not have been representative of
the larger population of high-risk women. Their sample was
recruited froma single center and, comparedwith our sample,
included fewer women with a history of breast cancer (31%),
more women who were premenopausal at PBSO (50%), and
no women who had undergone PM.
In addition to the cancer worry scale, we also adminis-
tered the intrusion subscale of the IES to assess cancer-
specific distress. No significant differences were observed in
the level of intrusive thoughts about breast and ovarian
cancer between the PBSO andGS groups. The cancer worry
scale can be viewed as a subclinical distress measure,
whereas the intrusive thought subscale of the IES is in-
tended to assess a more severe form of distress, capturing
symptoms of PTSD. In our study sample, approximately
10% of all women exhibited symptoms suggesting the pres-
ence of PTSD, with breast and ovarian cancer risk as an
underlying stressor. It is worth noting that, although PBSO
reduces objective cancer risk, it does not eliminate high
levels of cancer-specific distress in some women.
After controlling for possible confounders, a signifi-
cant difference was observed in breast cancer risk percep-
tion, with the PBSO group scoring significantly lower than
the GS group. A comparison between the pre- and post-
operative (retrospective) assessments of perceived breast
Table 3. Multivariate OR and 95% CIs for Women Who Had Opted for GS Compared With Women Who Had Undergone PBSO by Cancer Worries
in the Past 4 Weeks (worried v not worried)
Selected Item
% of Patients
OR
PBSO
(n  369)
GS
(n  477) 95% CI† P†
Worried about ovarian cancer 15.2 37.4 3.2 2.2 to 4.7  .001
Worried about breast cancer 43.0 61.0 1.3 0.9 to 1.8 .14
Worries affected mood 27.9 43.3 1.7 1.3 to 2.6  .001
Worries affected functioning 11.0 17.0 1.9 1.2 to 2.9  .01
Worried about other family members at risk 60.8 65.9 1.4 1.0 to 1.9  .05
Abbreviations: OR, odds ratio; GS, gynecologic screening; PBSO, prophylactic bilateral salpingo-oophorectomy.
Unadjusted percentages.
†All analyses were controlled for age, DNA status, parity, history of breast cancer, and prophylactic mastectomy.
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cancer risk indicated a decrease, on average, of 29% after
PBSO and 51% after both PBSO and PM. Our results sug-
gest that high-risk women benefit both medically and psy-
chologically from prophylactic surgery by the reduction of
both their objective cancer risk and their perceived risk of
developing cancer and that this benefit is the greatest among
women who undergo both ovarian and breast surgeries.
As expected, PBSO was associated with more endocrine
symptoms and worse sexual functioning than GS. The use of
HRT had relatively limited impact on the level of menopausal
and sexual symptoms in thePBSOgroup (detaileddata on this
issuewill be reported in a separate article). Although thePBSO
and GS groups included comparable numbers of sexually ac-
tive women, prophylactic surgery was associated with more
discomfort and less pleasure and satisfaction during sex. Post-
surgery increase in levels of menopausal symptoms and de-
clines in sexual functioning caused by estrogen deprivation
symptoms (eg, vaginal dryness, dyspareunia, and vasomotor
symptoms) have also been reported in other studies.17,18,35
However, no significant PBSO-GS differences in sexual func-
tioningwere detected in the study by Fry et al20 using the same
measure of sexual functioning. This may be because of their
smaller sample size and lower rates of sexually active women
(66.1%) compared with our investigation.
Our findings suggest that the beneficial QOL effects of
PBSO may outweigh the adverse effects because almost all
women who had undergone PBSO reported being highly
satisfied with the procedure. These findings are in line with
previous studies.18,19,37-39 The vast majority of women in
the PBSO group would undergo surgery again, whereas less
than two thirds of women undergoing GS would choose
screening again. Almost one third of women in the GS
group expressed the intention to undergo PBSO in the
future. These results suggest that high-risk women may
perceive GS as only a temporary preventive health strategy.
Given its multicenter nature and the relatively high
response rate, we believe that the study sample was repre-
sentative of high-risk women in the Netherlands. However,
some possible limitations of our study should be noted.
First, we did not include measures of perceived anxiety
reduction or a retrospective report of changes in self-
perceived cancer risk in the GS group. Given the cross-
sectional study design and the longitudinal nature of
screening itself, there was no clear reference point in time
for the GS group that would be comparable to that for
womenwho had undergone PBSO.Data fromour ongoing,
longitudinal study will be able to inform this issue. Second,
because of the cross-sectional design of the study, possible
changes in QOL over time induced by prophylactic treat-
ment or screening could not be assessed prospectively. A
prospective,multicenter study is currently being conducted
to obtain a more thorough picture of the QOL and symp-
tom experience over time of high-risk women who opt for
PBSO versus GS. Third, women who had undergone PBSO
or GSmay come from slightly different populations regard-
ing their objective risk of developing ovarian cancer because
more than half of the GS group did not have DNA testing.
Although we controlled for known risk factors in our anal-
yses, statistical adjustments for confounding factors may
not have entirely ruled out possible selection bias resulting
from nonrandomized comparison groups. However, given
the known benefits of PBSO for ovarian cancer risk reduc-
tion and the unknown efficacy of the current GS techniques
in early ovarian cancer detection, a randomized trial is not
feasible and would not be ethical.
In conclusion, this study has documented both benefi-
cial and adverse QOL effects associated with the two major
health strategies for ovarian cancer in high-risk women.
Physicians should discuss both the pros and cons of PBSO
andGSwith high-risk women seekingmedical advice about
their riskmanagement. Among the benefits, reduced cancer
worries after PBSO should be emphasized. The likely in-
crease of climacteric and sexual symptoms, which may not
be alleviated by the postsurgical use of HRT, should be
included in discussions of adverse effects of PBSO. Balanced
information will help clinicians and high-risk women to
make informed decisions about the optimal preventive
health strategy. Finally, our results indicate that a minority
of oophorectomized women may experience high levels of
distress after prophylactic treatment. Such women should
be identified in a timelymanner, and they should be offered
(additional) psychosocial care after PBSO.
■ ■ ■
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